4% Tetrasodium EDTA to Prevent Central Venous Access Device-Associated Complications: A Randomized Clinical Trial - PubMed
5 hours ago
- #ICU Care
- #Catheter Complications
- #Randomized Trial
- The study investigated whether a 4% tetrasodium EDTA locking fluid reduces complications associated with central venous access devices in ICU adults.
- It was a pragmatic, triple-blind, multicenter, cluster-randomized crossover trial conducted in 6 Canadian hospitals.
- The primary outcome was a composite of catheter-associated bloodstream infection, occlusion requiring alteplase, or removal due to occlusion.
- Results showed a lower incidence rate of the primary outcome in the t-EDTA group (13.1 per 1000 catheter-days) vs control (19.9 per 1000 catheter-days).
- The use of 4% t-EDTA significantly reduced the composite outcome compared to control, with a rate ratio of 0.68.